- Stocks
- Healthcare
- NASDAQ: DNLI

Price (delayed)

$22.9

Market cap

$3.13B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.6

Enterprise value

$2.96B

Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing

The quick ratio has soared by 60% year-on-year and by 20% since the previous quarter

Denali Therapeutics's equity has increased by 28% QoQ and by 8% YoY

DNLI's revenue has soared by 123% year-on-year but it is down by 2% since the previous quarter

Denali Therapeutics's gross profit has surged by 123% YoY but it has decreased by 2% QoQ

The net income is down by 12% year-on-year and by 8% since the previous quarter

The EPS has decreased by 9% YoY and by 5% from the previous quarter

What are the main financial stats of DNLI

Market
Valuations
Earnings

Shares outstanding

136.68M

Market cap

$3.13B

Enterprise value

$2.96B

Price to earnings (P/E)

N/A

Price to book (P/B)

2.98

Price to sales (P/S)

26.5

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

27.34

Revenue

$108.46M

EBIT

-$325.97M

EBITDA

-$315.59M

Free cash flow

-$262.55M

Per share
Balance sheet
Liquidity

EPS

-$2.6

Free cash flow per share

-$2.09

Book value per share

$7.68

Revenue per share

$0.86

TBVPS

$11.63

Total assets

$1.46B

Total liabilities

$417.81M

Debt

$53.03M

Equity

$1.04B

Working capital

$1.01B

Debt to equity

0.05

Current ratio

3.77

Quick ratio

3.67

Net debt/EBITDA

0.52

Margins
Efficiency
Dividend

EBITDA margin

-291%

Gross margin

100%

Net margin

-300.6%

Operating margin

-314.2%

Return on assets

-24.6%

Return on equity

-35.7%

Return on invested capital

-36.9%

Return on capital employed

-29.7%

Return on sales

-300.5%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Denali Therapeutics stock price performed over time

Intraday

-0.04%

1 week

-1.84%

1 month

-11.62%

1 year

-32.82%

YTD

-17.66%

QTD

-17.66%

How have Denali Therapeutics's revenue and profit performed over time

Revenue

$108.46M

Gross profit

$108.46M

Operating income

-$340.74M

Net income

-$325.99M

Gross margin

100%

Net margin

-300.6%

DNLI's revenue has soared by 123% year-on-year but it is down by 2% since the previous quarter

Denali Therapeutics's gross profit has surged by 123% YoY but it has decreased by 2% QoQ

Denali Therapeutics's net margin has increased by 50% YoY but it has decreased by 10% from the previous quarter

DNLI's operating margin is up by 48% year-on-year but it is down by 11% since the previous quarter

What is Denali Therapeutics's growth rate over time

What is Denali Therapeutics stock price valuation

P/E

N/A

P/B

2.98

P/S

26.5

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

27.34

The EPS has decreased by 9% YoY and by 5% from the previous quarter

DNLI's price to book (P/B) is 38% less than its 5-year quarterly average of 4.8 and 29% less than its last 4 quarters average of 4.2

Denali Therapeutics's equity has increased by 28% QoQ and by 8% YoY

DNLI's revenue has soared by 123% year-on-year but it is down by 2% since the previous quarter

The stock's price to sales (P/S) is 89% less than its 5-year quarterly average of 237.3 and 28% less than its last 4 quarters average of 36.6

How efficient is Denali Therapeutics business performance

The ROS has increased by 50% YoY but it has decreased by 10% from the previous quarter

The return on equity has declined by 28% year-on-year and by 6% since the previous quarter

The return on invested capital has declined by 27% year-on-year and by 3.1% since the previous quarter

The return on assets has declined by 25% year-on-year and by 6% since the previous quarter

What is DNLI's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for DNLI.

How did Denali Therapeutics financials performed over time

The quick ratio has soared by 60% year-on-year and by 20% since the previous quarter

The current ratio has soared by 59% YoY and by 19% from the previous quarter

Denali Therapeutics's debt is 95% less than its equity

DNLI's debt to equity is down by 38% since the previous quarter and by 17% year-on-year

Denali Therapeutics's equity has increased by 28% QoQ and by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.